Alchemia Limited – Product Pipeline Review – H2 2011
Summary
Global Market Direct’s pharmaceuticals report, “Alchemia Limited - Product Pipeline Review - H2 2011” provides data on the Alchemia Limited’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Alchemia Limited’s corporate website, SEC filings, investor presentations and featured press releases, both from Alchemia Limited and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
Reasons to buy
Summary
Global Market Direct’s pharmaceuticals report, “Alchemia Limited - Product Pipeline Review - H2 2011” provides data on the Alchemia Limited’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Alchemia Limited’s corporate website, SEC filings, investor presentations and featured press releases, both from Alchemia Limited and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
- Alchemia Limited - Brief Alchemia Limited overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Alchemia Limited human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Alchemia Limited with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Alchemia Limited’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Alchemia Limited’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Alchemia Limited in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Alchemia Limited’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Alchemia Limited.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Alchemia Limited and identify potential opportunities in those areas.
Alchemia Limited Snapshot
Alchemia Limited Overview
Key Information
Key Facts
Alchemia Limited – Research and Development Overview
Key Therapeutic Areas
Alchemia Limited – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Alchemia Limited – Pipeline Products Glance
Alchemia Limited – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Alchemia Limited–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Alchemia Limited – Drug Profiles
Antibiotic Programme
Product Description
Mechanism of Action
R&D Progress
FOLF(HA)Iri
Product Description
Mechanism of Action
R&D Progress
HA-Irinotecan
Product Description
Mechanism of Action
R&D Progress
HyACT-Avastin
Product Description
Mechanism of Action
R&D Progress
HyACT-Erbitux
Product Description
Mechanism of Action
R&D Progress
HyACT-Gemzar
Product Description
Mechanism of Action
R&D Progress
HyACT-Navelbine
Product Description
Mechanism of Action
R&D Progress
HyACT-Paraplatin
Product Description
Mechanism of Action
R&D Progress
Somatostatin Programme
Product Description
Mechanism of Action
R&D Progress
VAST Based Drug For Obesity
Product Description
Mechanism of Action
R&D Progress
VAST Based Drug For Pain
Product Description
Mechanism of Action
R&D Progress
Alchemia Limited – Pipeline Analysis
Alchemia Limited – Pipeline Products by Therapeutic Class
Alchemia Limited - Pipeline Products By Target
Alchemia Limited – Pipeline Products by Route of Administration
Alchemia Limited – Pipeline Products by Molecule Type
Alchemia Limited – Recent Pipeline Updates
Alchemia Limited - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
ACL16907
VAST Based Drug For Obesity
Alchemia Limited – Company Statement
Alchemia Limited – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
May 29, 2007: Alchemia Limited Announces Positive Final Data From HyCAMP Phase II Trial In Metastatic Colorectal Cancer
Jul 12, 2010: Alchemia’s Phase III Cancer Trial Adopted By National Institute Of Health Research Clinical Research Network
Sep 09, 2011: Alchemia Initiates Phase II Trial Of HA-Irinotecan In Small Cell Lung Cancer
Jun 07, 2002: Meditech Announces Positive HyDOX Results
May 04, 2010: Alchemia Receives $1M Grant Support For The Discovery Of Novel Pain Killers With Reduced Side Effects
Feb 01, 2008: Alchemia Announces Successful Pre-IND Meeting with the US FDA.
Financial Deals Landscape
Alchemia Limited, Deals Summary
Alchemia Limited, Pharmaceuticals & Healthcare, Deal Details
Partnerships
Alchemia Expands Co-Marketing Agreement With Dr Reddy's Laboratories
Emisphere Technologies Enters Into Research Collaboration With Alchemia
Alchemia Signs An Agreement With Dr Reddy's Laboratories
Alchemia Enters Into Co-Development Agreement With Euroscreen
Alchemia Enters Into Co-Development Agreement With TetraQ
Licensing Agreements
Alchemia Enters Into Licensing Agreement With SDP Technology
Equity Offering
Alchemia Completes Rights Issue Of $14 Million
Alchemia Completes Private Placement Of $13 Million
Alchemia Completes Private Placement Of $4 Million
Alchemia Completes Private Placement Of $11 Million
Acquisition
Alchemia Acquires Meditech
Cytopia Divests Its Stake In Alchemia
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Alchemia Limited – Pipeline by Therapy Area and Indication, H2 2011
Alchemia Limited – Pipeline by Stage of Development, H2 2011
Alchemia Limited – Monotherapy Products in Pipeline, H2 2011
Alchemia Limited – Phase III, H2 2011
Alchemia Limited - Pipeline By Therapeutic Class, H2 2011
Alchemia Limited - Pipeline By Target, H2 2011
Alchemia Limited – Pipeline By Route of Administration, H2 2011
Alchemia Limited – Pipeline By Molecule Type, H2 2011
Alchemia Limited – Recent Pipeline Updates, H2 2011
Alchemia Limited - Discontinued Pipeline Products, 2010
Alchemia Limited, Subsidiaries
Alchemia Limited, Deals Summary
Alchemia Expands Co-Marketing Agreement With Dr Reddy's Laboratories
Emisphere Technologies Enters Into Research Collaboration With Alchemia
Alchemia Signs An Agreement With Dr Reddy's Laboratories
Alchemia Enters Into Co-Development Agreement With Euroscreen
Alchemia Enters Into Co-Development Agreement With TetraQ
Alchemia Enters Into Licensing Agreement With SDP Technology
Alchemia Completes Rights Issue Of $14 Million
Alchemia Completes Private Placement Of $13 Million
Alchemia Completes Private Placement Of $4 Million
Alchemia Completes Private Placement Of $11 Million
Alchemia Acquires Meditech
Cytopia Divests Its Stake In Alchemia
LIST OF FIGURES
Alchemia Limited – Pipeline by Therapy Area and Indication, H2 2011
Alchemia Limited – Pipeline by Stage of Development, H2 2011
Alchemia Limited – Monotherapy Products in Pipeline, H2 2011
Alchemia Limited – Pipeline By Therapeutic Class, H2 2011
Alchemia Limited - Pipeline By Target, H2 2011
Alchemia Limited – Pipeline By Route of Administration, H2 2011
Alchemia Limited – Pipeline By Molecule Type, H2 2011
Alchemia Limited Overview
Key Information
Key Facts
Alchemia Limited – Research and Development Overview
Key Therapeutic Areas
Alchemia Limited – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Alchemia Limited – Pipeline Products Glance
Alchemia Limited – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Alchemia Limited–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Alchemia Limited – Drug Profiles
Antibiotic Programme
Product Description
Mechanism of Action
R&D Progress
FOLF(HA)Iri
Product Description
Mechanism of Action
R&D Progress
HA-Irinotecan
Product Description
Mechanism of Action
R&D Progress
HyACT-Avastin
Product Description
Mechanism of Action
R&D Progress
HyACT-Erbitux
Product Description
Mechanism of Action
R&D Progress
HyACT-Gemzar
Product Description
Mechanism of Action
R&D Progress
HyACT-Navelbine
Product Description
Mechanism of Action
R&D Progress
HyACT-Paraplatin
Product Description
Mechanism of Action
R&D Progress
Somatostatin Programme
Product Description
Mechanism of Action
R&D Progress
VAST Based Drug For Obesity
Product Description
Mechanism of Action
R&D Progress
VAST Based Drug For Pain
Product Description
Mechanism of Action
R&D Progress
Alchemia Limited – Pipeline Analysis
Alchemia Limited – Pipeline Products by Therapeutic Class
Alchemia Limited - Pipeline Products By Target
Alchemia Limited – Pipeline Products by Route of Administration
Alchemia Limited – Pipeline Products by Molecule Type
Alchemia Limited – Recent Pipeline Updates
Alchemia Limited - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
ACL16907
VAST Based Drug For Obesity
Alchemia Limited – Company Statement
Alchemia Limited – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
May 29, 2007: Alchemia Limited Announces Positive Final Data From HyCAMP Phase II Trial In Metastatic Colorectal Cancer
Jul 12, 2010: Alchemia’s Phase III Cancer Trial Adopted By National Institute Of Health Research Clinical Research Network
Sep 09, 2011: Alchemia Initiates Phase II Trial Of HA-Irinotecan In Small Cell Lung Cancer
Jun 07, 2002: Meditech Announces Positive HyDOX Results
May 04, 2010: Alchemia Receives $1M Grant Support For The Discovery Of Novel Pain Killers With Reduced Side Effects
Feb 01, 2008: Alchemia Announces Successful Pre-IND Meeting with the US FDA.
Financial Deals Landscape
Alchemia Limited, Deals Summary
Alchemia Limited, Pharmaceuticals & Healthcare, Deal Details
Partnerships
Alchemia Expands Co-Marketing Agreement With Dr Reddy's Laboratories
Emisphere Technologies Enters Into Research Collaboration With Alchemia
Alchemia Signs An Agreement With Dr Reddy's Laboratories
Alchemia Enters Into Co-Development Agreement With Euroscreen
Alchemia Enters Into Co-Development Agreement With TetraQ
Licensing Agreements
Alchemia Enters Into Licensing Agreement With SDP Technology
Equity Offering
Alchemia Completes Rights Issue Of $14 Million
Alchemia Completes Private Placement Of $13 Million
Alchemia Completes Private Placement Of $4 Million
Alchemia Completes Private Placement Of $11 Million
Acquisition
Alchemia Acquires Meditech
Cytopia Divests Its Stake In Alchemia
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Alchemia Limited – Pipeline by Therapy Area and Indication, H2 2011
Alchemia Limited – Pipeline by Stage of Development, H2 2011
Alchemia Limited – Monotherapy Products in Pipeline, H2 2011
Alchemia Limited – Phase III, H2 2011
Alchemia Limited - Pipeline By Therapeutic Class, H2 2011
Alchemia Limited - Pipeline By Target, H2 2011
Alchemia Limited – Pipeline By Route of Administration, H2 2011
Alchemia Limited – Pipeline By Molecule Type, H2 2011
Alchemia Limited – Recent Pipeline Updates, H2 2011
Alchemia Limited - Discontinued Pipeline Products, 2010
Alchemia Limited, Subsidiaries
Alchemia Limited, Deals Summary
Alchemia Expands Co-Marketing Agreement With Dr Reddy's Laboratories
Emisphere Technologies Enters Into Research Collaboration With Alchemia
Alchemia Signs An Agreement With Dr Reddy's Laboratories
Alchemia Enters Into Co-Development Agreement With Euroscreen
Alchemia Enters Into Co-Development Agreement With TetraQ
Alchemia Enters Into Licensing Agreement With SDP Technology
Alchemia Completes Rights Issue Of $14 Million
Alchemia Completes Private Placement Of $13 Million
Alchemia Completes Private Placement Of $4 Million
Alchemia Completes Private Placement Of $11 Million
Alchemia Acquires Meditech
Cytopia Divests Its Stake In Alchemia
LIST OF FIGURES
Alchemia Limited – Pipeline by Therapy Area and Indication, H2 2011
Alchemia Limited – Pipeline by Stage of Development, H2 2011
Alchemia Limited – Monotherapy Products in Pipeline, H2 2011
Alchemia Limited – Pipeline By Therapeutic Class, H2 2011
Alchemia Limited - Pipeline By Target, H2 2011
Alchemia Limited – Pipeline By Route of Administration, H2 2011
Alchemia Limited – Pipeline By Molecule Type, H2 2011